Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

Overview of attention for article published in BMC Cancer, May 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 1 news outlet

twitter: 29 X users

Citations

dimensions_citation: 40 Dimensions

Readers on

mendeley: 44 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 42 X posts from 29 X users, with an upper bound of 156,692 followers.

RT @PGrivasMDPhD: Negative trials still teach us a lot! Thanks @scserendipity1 & Team for working hard on it!We need to further define the…

31 May 2021

Reply Repost Favourite

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) https://t.co/9tCJEmEpzW #hvhebron #onco [Text complet] @BMC_series

27 May 2021

Reply Repost Favourite

RT @montypal: 3 cheers to @PGrivasMDPhD @scserendipity1 @ZakhariaYousef @AlvaAjjai @AndreaNecchi @shilpaonc @sandysrimd @y_loriot @drenriqu…

27 May 2021

Reply Repost Favourite

New 3i Investigator Article Alert!! Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) https://t.co/9EwV0uZZVC #sciencetwitter #academictwitter

26 May 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 38 additional X posts.